Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

Data from the Phase II trial saw three of the seven patients dosed with CAN-2409 surviving for more than 35 months.

Candel Therapeutics' recent phase 2 results in pancreatic cancer showed promising median survival but led to a 20% stock drop ...

▎药明康德内容团队编辑默沙东（MSD）今日宣布，美国FDA已接受该公司为重磅免疫疗法Keytruda递交的补充生物制品许可申请（sBLA），寻求批准Keytruda作为手术前的新辅助疗法，用于治疗可切除局部晚期头颈部鳞状细胞癌（LA-HNSCC）患者，随后联合标准放疗（有或无顺铂）作为辅助治疗，然后再作为单药进行辅助治疗。FDA同时授 ...